Long-term Survival with Ipilimumab: Experience from a National Expanded Access Program for Patients with Melanoma. [electronic resource]
Producer: 20160208Description: 6303-10 p. digitalISSN:- 1791-7530
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal -- therapeutic use
- Antineoplastic Agents -- therapeutic use
- C-Reactive Protein -- metabolism
- Drug Resistance, Neoplasm -- drug effects
- Female
- Follow-Up Studies
- Humans
- Ipilimumab
- L-Lactate Dehydrogenase -- metabolism
- Male
- Melanoma -- drug therapy
- Middle Aged
- Neoplasm Metastasis
- Neoplasm Recurrence, Local -- drug therapy
- Neoplasm Staging
- Prognosis
- Safety
- Salvage Therapy
- Survival Rate
- Time Factors
- Young Adult
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.